Supriya Lifescience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stocks to watch on Wednesday, May 29, 2024: The Sensex and Nifty benchmarks are expected to open lower on...

Revenues rose 33% YoY to Rs 140 crore in Q3FY24. Earnings before interest, taxes, depreciation and amortisation (EBITDA) for Q3FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA margin of 29.6% in Q3FY24, as opposed to 13.4%, an improvement of 1620 basis points.

Q3 results today: Approximately 63 companies will release their Q3 quarter results today on February 7

Supriya Lifescience, an active pharmaceutical ingredient (API) maker based in Mumbai, aims to double its revenue in the next three years. The company plans to achieve this goal by expanding its product basket with the addition of six to seven molecules, targeting areas such as anti-anxiety, anesthesia, and anti-diabetes.

If one looks at corporate announcements, a large number of small and mid-caps pharma companies are announcing one or the other thing either about US FDA or European authorities giving approval or inspection. While the large players had moved to international markets a long time back, a number of small companies that had domestic focussed business are also moving into the developed global markets. Will this lead to re-rating?